WALTHAM, Mass.–(BUSINESS WIRE)–Revity, Inc. (NYSE: RVTY) has announced an expanded partnership with Genomics England to provide DNA sequencing services for newborn screening. The new contract builds upon a prior agreement for DNA extraction services and will enable Revvity to offer a complete end-to-end solution. This will include a localized lab facility for faster DNA extraction and sequencing, aimed at advancing the screening process for rare genetic conditions.
The Generation Study, a groundbreaking initiative led by Genomics England in collaboration with the National Health Service (NHS), aims to screen up to 100,000 newborns for more than 200 rare genetic disorders. The results of the study will guide future decisions on the use of whole genome sequencing (WGS) in newborn screening. Proactive screening could help doctors identify risks for genetic conditions earlier, enabling timely interventions and personalized care.
Dr. Madhuri Hegde, Revvity’s Senior Vice President and Chief Scientific Officer, expressed excitement about the expanded partnership. “We are proud to support Genomics England in expanding access to genomic sequencing in England. Our integrated solution and localized lab facility will provide faster, reliable sequencing data, contributing to this critical program that strengthens newborn health,” she said.
Dr. Ellen Thomas, Chief Medical Officer at Genomics England, emphasized the importance of the collaboration. “This partnership with Revvity is a significant step in our mission to generate evidence on the use of genomic sequencing in newborn screening. By integrating sequencing with DNA extraction, we can streamline the process, provide faster results, and help families access care sooner.”
This collaboration marks a key development in the growing field of genomic medicine and newborn screening.
Related topics:
